TCGA-CF-A47X-01A-31R-A23W-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 12.61498029
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.230
- PANCREAS_BETA_CELLS+0.190
- HEDGEHOG_SIGNALING+0.100
- ESTROGEN_RESPONSE_EARLY+0.020
- ESTROGEN_RESPONSE_LATE-0.050
- PEROXISOME-0.050
- BILE_ACID_METABOLISM-0.070
- XENOBIOTIC_METABOLISM-0.070
- TNFA_SIGNALING_VIA_NFKB-0.090
- SPERMATOGENESIS-0.100
Top 10 suppressed
- E2F_TARGETS-0.650
- G2M_CHECKPOINT-0.610
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.510
- DNA_REPAIR-0.460
- MTORC1_SIGNALING-0.450
- MYC_TARGETS_V1-0.450
- INTERFERON_ALPHA_RESPONSE-0.440
- MITOTIC_SPINDLE-0.420
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.410
- ALLOGRAFT_REJECTION-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG761 | — | — | 0.925 |
| 2 | MNG540 | — | — | 0.922 |
| 3 | TCGA-E7-A3Y1-01A-11R-A22U-07 | — | — | 0.917 |
| 4 | TCGA-CF-A47Y-01A-11R-A23W-07 | — | — | 0.913 |
| 5 | SRR1516050 | — | — | 0.911 |
| 6 | BS_0Y66ZBWE | low-grade glioma | — | 0.909 |
| 7 | c7d31245-5d71-4a23-8a33-4f83c4718e20 | — | — | 0.909 |
| 8 | SRR6013517 | — | cohortA1 | 0.908 |
| 9 | 8ad884fa-e426-4bc0-960d-08db42d341da | — | — | 0.907 |
| 10 | TCGA-E9-A245-01A-22R-A16F-07 | — | B | 0.906 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 4 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.230 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.190 | Cobimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.100 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.020 | Inavolisib | — uncovered |